JFG
MRTX

Jefferies Financial Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Jefferies Financial Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-173,665
Closed -$9.76M – 2082
2023
Q3 		$7.56M Buy
173,665
+30,696
+21% +$1.1M 0.07% 231
2023
Q2 		$5.17M Buy
142,969
+92,549
+184% +$3.81M 0.05% 352
2023
Q1 		$1.87M Buy
50,420
+18,279
+57% +$822K 0.02% 678
2022
Q4 		$1.46M Buy
+32,141
New +$2.08M 0.01% 767

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jefferies Financial Group's MRTX Position: Q4 2023 in Review

Jefferies Financial Group sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 173,665 shares — an estimated $9.76M sold.

Jefferies Financial Group first reported a position in MRTX in Q4 2022 and held it in 4 quarters. The position peaked at $7.56M in Q3 2023. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Jefferies Financial Group reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Jefferies Financial Group sold 173,665 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $9.76M.
  • Jefferies Financial Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2022 and held it in 4 quarters.
  • Jefferies Financial Group's Mirati Therapeutics, Inc. Common Stock position peaked at $7.56M in Q3 2023.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Jefferies Financial Group's 13F filing for Q4 2023, filed 14 Feb 2024.